Quick Answer
SANGAMO THERAPEUTICS, INC reported Net Income Loss of -$122.93 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -25.5% in Net Income Loss from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$6.15 million | Q4 2013: -$8.14 million | Q1 2014: -$7.57 million | Q2 2014: -$6.98 million | Q3 2014: -$7.55 million | Q4 2014: -$4.32 million | Q1 2015: -$5.32 million | Q2 2015: -$12.13 million | Q3 2015: -$9.25 million | Q4 2015: -$14.01 million | Q1 2016: -$16.49 million | Q2 2016: -$26.58 million | Q3 2016: -$18.97 million | Q4 2016: -$9.62 million | Q1 2017: -$16.63 million | Q2 2017: -$12.49 million | Q3 2017: -$12.35 million | Q4 2017: -$13.09 million | Q1 2018: -$20.19 million | Q2 2018: -$16.64 million | Q3 2018: -$12.84 million | Q4 2018: -$18.66 million | Q1 2019: -$42.15 million | Q2 2019: -$30.28 million | Q3 2019: -$27.31 million | Q4 2019: $4.56 million | Q1 2020: -$42.91 million | Q2 2020: -$35.93 million | Q3 2020: -$1.55 million | Q4 2020: -$40.60 million | Q1 2021: -$45.93 million | Q2 2021: -$47.17 million | Q3 2021: -$47.69 million | Q1 2022: -$43.98 million | Q2 2022: -$43.17 million | Q3 2022: -$53.16 million | Q1 2023: $21.13 million | Q2 2023: -$114.51 million | Q3 2023: -$104.16 million | Q1 2024: -$49.09 million | Q2 2024: -$36.13 million | Q3 2024: $10.67 million | Q1 2025: -$30.60 million | Q2 2025: -$19.99 million | Q3 2025: -$34.93 million.
- Over the full 17 years of available data (2009 to 2025), SANGAMO THERAPEUTICS, INC's Net Income Loss has declined by 561.4%.
- Historical annual values: Fiscal year 2025: -$122.93 million | Fiscal year 2024: -$97.94 million | Fiscal year 2023: -$257.83 million | Fiscal year 2022: -$192.28 million | Fiscal year 2021: -$178.29 million | Fiscal year 2020: -$121.00 million | Fiscal year 2019: -$95.19 million | Fiscal year 2018: -$68.33 million | Fiscal year 2017: -$54.57 million | Fiscal year 2016: -$71.66 million | Fiscal year 2015: -$40.70 million | Fiscal year 2014: -$26.42 million | Fiscal year 2013: -$26.62 million | Fiscal year 2012: -$22.26 million | Fiscal year 2011: -$35.75 million | Fiscal year 2010: -$24.85 million | Fiscal year 2009: -$18.59 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: